Medical Doctor Program year 2021 Reported 2019–2021 Source: CMS Open Payments, 2026 publication

Geoffrey Dolan

Rheumatology Long Beach, CA Medical Doctor

NPI 1811910847 CMS profile 82344

3816 Woodruff Ave, Suite 412, Long Beach, CA 90808

Open in the dashboard

General payments

$9,514

530 records reported · program years 2019–2021

Research payments

$0

Paid to them · None reported · program years 2019–2021

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$2,132 paid to institutions, not to them · program year 2020

Through program year 2021, Geoffrey Dolan of Long Beach, CA is reported in the CMS Open Payments database as having received $9,514 across 530 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $2,132 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 71st percentile of Rheumatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2021 General $2,989 167
2020 General $2,860 149
2019 General $3,665 214

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Geoffrey Dolan
  • Rheumatology median
  • Middle half of Rheumatology
  • National median

In program year 2025, general payments to Geoffrey Dolan were reported at $0. Among 4,454 Rheumatology profiles paid that year, the median was $903 and the middle half received between $171 and $2,775.

Show as a table
Year Geoffrey Dolan Rheumatology median Middle half National median
2019 $3,665 $744 $153–$2,687 $163
2020 $2,860 $462 $98–$2,027 $114
2021 $2,989 $531 $101–$2,153 $132
2022 $0 $627 $125–$2,303 $149
2023 $0 $741 $145–$2,524 $160
2024 $0 $830 $166–$2,660 $164
2025 $0 $903 $171–$2,775 $169

Breakdown

Who paid General payments · program years 2019–2021
  1. AbbVie, Inc. $2,224 125 payments
  2. Amgen Inc. $2,054 93 payments
  3. Horizon Therapeutics plc $750 53 payments
  4. Janssen Biotech, Inc. $689 39 payments
  5. Lilly USA, LLC $643 35 payments
  6. Novartis Pharmaceuticals Corporation $577 42 payments
  7. Pfizer Inc. $442 34 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $318 12 payments
  9. Celgene Corporation $267 14 payments
  10. Amarin Pharma Inc. $237 13 payments
  11. Other $1,314 70 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2021
  1. Food and Beverage $9,510 528 payments
  2. Education $4 2 payments
Products named General payments · program years 2019–2021
  1. RINVOQ $984 45 payments
  2. HUMIRA $946 64 payments
  3. Prolia $753 38 payments
  4. TALTZ $642 34 payments
  5. Otezla $553 20 payments
  6. Enbrel $545 23 payments
  7. COSENTYX $539 40 payments
  8. RAYOS Rayos $461 34 payments
  9. RAYOS Rayos $461 34 payments
  10. RAYOS Rayos $461 34 payments
  11. Other $6,960 391 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

530 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Rheumatology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2021

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record